Use of Ketamine for Mental Disorders Rising While New Therapies Emerge
Pasithea Therapeutics Corp. (KTTA)
Company Research
Source: PR Newswire
PALM BEACH, Fla., Nov. 17, 2021 /PRNewswire/ -- FinancialNewsMedia.com News Commentary - The uses of Ketamine for a variety of therapies are growing. An expanding number of clinics are offering ketamine infusion therapy for the treatment of mental health disorders and there is also a rising number of local manufacturers and increasing R&D activities in anesthetics are anticipated to boost the market development. Factors like the rising prevalence of chronic diseases, the growing aging population, and rising utilization of anesthetics are projected to drive the market development. In addition, technological advancements support the development of the market. The geriatric population is at higher risk of getting affected with chronic diseases like diabetes, CVD, CRD and mental health disorders that leads to rising interest in medical procedures. Accordingly, the rising aging population is additionally anticipated to drive the development of the market. Rising number of minimally invasiv
Show less
Read more
Impact Snapshot
Event Time:
KTTA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KTTA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KTTA alerts
High impacting Pasithea Therapeutics Corp. news events
Weekly update
A roundup of the hottest topics
KTTA
News
- Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers [Yahoo! Finance]Yahoo! Finance
- Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated CancersGlobeNewswire
- Pasithea Therapeutics Announces Opening of Enrollment in the U.S. for its Phase 1 Trial of PAS-004 [Yahoo! Finance]Yahoo! Finance
- Pasithea Therapeutics Announces Opening of Enrollment in the U.S. for its Phase 1 Trial of PAS-004GlobeNewswire
KTTA
Sec Filings
- 4/5/24 - Form 4/A
- 4/5/24 - Form 4/A
- 4/5/24 - Form 4/A
- KTTA's page on the SEC website